{
  "docId": "019de074-1cfe-7508-8ae3-4ba4db03f42e",
  "docSlug": "98d74dc525a4b13d13a1ee51c3af4583",
  "documentTitle": "Kymera | Results Presentation Deck | 63 slides",
  "authorId": "kymera",
  "authorName": "Kymera",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-12-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 14,
  "pageCount": 63,
  "prevPage": 13,
  "nextPage": 15,
  "slideType": "key_takeaways",
  "function": "summarize",
  "density": "balanced",
  "nDataPoints": 3,
  "notes": "DL = Dose Level; DLT = Dose Limiting Toxicity; SAE = Serious Adverse Event.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de074-1cfe-7508-8ae3-4ba4db03f42e/14",
  "deckHref": "/decks/019de074-1cfe-7508-8ae3-4ba4db03f42e",
  "deckJsonHref": "/decks/019de074-1cfe-7508-8ae3-4ba4db03f42e.json",
  "deckAnchorHref": "/decks/019de074-1cfe-7508-8ae3-4ba4db03f42e#slide-14",
  "components": [
    {
      "bbox": {
        "h": 0.68,
        "w": 0.86,
        "x": 0.07,
        "y": 0.18
      },
      "kind": "list",
      "text": "Accrual to first dose level completed\nSTAT3 degradation in blood at first dose level consistent with preclinical predictions, with mean maximum degradation following first 2 doses of Cycle 1 averaging 66%, with maximum knockdown of up to 86%\nAt least 48h of target degradation observed that in preclinical species led to robust antitumor activity in STAT3 sensitive preclinical models\nDL1 level generally well-tolerated with no DLTs or treatment-related SAEs\nDL2 currently enrolling patients\nDL3-4 expected to be clinically active doses",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "21bb7fc3-3b1b-442d-874e-552b09cc8581",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.86,
        "x": 0.07,
        "y": 0.04
      },
      "kind": "title",
      "text": "Demonstration of Initial Proof-of-Mechanism (POM) for KT-333",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "91ee904f-0eca-4dfc-abbf-23c3959f63c9",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 15,
      "from": 5,
      "beatId": "69f2d34e-b7ab-4885-8215-0582cdf92a83",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Agitation",
      "beatSlug": "problem-agitate-solution-agitate-make-it-worse",
      "evidence": "Discussion of current treatment limitations and Kymera's solution",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Development",
      "parentBeatSlug": "development"
    }
  ],
  "loops": [
    {
      "to": 14,
      "from": 13,
      "name": "Before After",
      "slug": "21-before-after",
      "bestFor": "Product demos, process improvements, ROI justification",
      "matchId": "d2ba16ef-fee8-4e4f-a8a2-6322f08cccfe",
      "evidence": "STAT3 degradation in blood at dose level 1",
      "position": 0,
      "objective": "Demonstrate initial proof-of-mechanism for KT-333",
      "structure": "The Old Way (Pain) -> The Moment of Change -> The New Way (Glory) -> The Measurable Delta",
      "confidence": 0.8,
      "description": "Show the dramatic contrast between the old way and the new way through side-by-side comparison"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}